Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study

SF Mohammed, BA Borlaug, VL Roger… - Circulation: Heart …, 2012 - Am Heart Assoc
SF Mohammed, BA Borlaug, VL Roger, SA Mirzoyev, RJ Rodeheffer, JA Chirinos
Circulation: Heart Failure, 2012Am Heart Assoc
Background—Patients with heart failure and preserved ejection fraction (HFpEF) display
increased adiposity and multiple comorbidities, factors that in themselves may influence
cardiovascular structure and function. This has sparked debate as to whether HFpEF
represents a distinct disease or an amalgamation of comorbidities. We hypothesized that
fundamental cardiovascular structural and functional alterations are characteristic of HFpEF,
even after accounting for body size and comorbidities. Methods and Results—Comorbidity …
Background
Patients with heart failure and preserved ejection fraction (HFpEF) display increased adiposity and multiple comorbidities, factors that in themselves may influence cardiovascular structure and function. This has sparked debate as to whether HFpEF represents a distinct disease or an amalgamation of comorbidities. We hypothesized that fundamental cardiovascular structural and functional alterations are characteristic of HFpEF, even after accounting for body size and comorbidities.
Methods and Results
Comorbidity-adjusted cardiovascular structural and functional parameters scaled to independently generated and age-appropriate allometric powers were compared in community-based cohorts of HFpEF patients (n=386) and age/sex-matched healthy n=193 and hypertensive, n=386 controls. Within HFpEF patients, body size and concomitant comorbidity-adjusted cardiovascular structural and functional parameters and survival were compared in those with and without individual comorbidities. Among HFpEF patients, comorbidities (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clinical, structural, functional, and prognostic profiles. However, after accounting for age, sex, body size, and comorbidities, greater concentric hypertrophy, atrial enlargement and systolic, diastolic, and vascular dysfunction were consistently observed in HFpEF compared with age/sex-matched normotensive and hypertensive.
Conclusions
Comorbidities influence ventricular-vascular properties and outcomes in HFpEF, yet fundamental disease-specific changes in cardiovascular structure and function underlie this disorder. These data support the search for mechanistically targeted therapies in this disease.
Am Heart Assoc